Aravive — Versartis — Technical Presentation (September 2016)
15 slides from Aravive's technical presentation, Sep 2, 2016
Slide 1: HbA1c over Two Years of Treatment with Somavaratan (VRS-317) in Children with GHD
Will Charlton1, Daniela Rogoff1, Eric Humphriss1, Kelly DiTrapani1, Philippe F. Backeljauw2 1Versartis, Inc, Menlo Park, CA; 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA HbA1c over Two Years of Treatment with Somavaratan (VRS-317) in Children with Growth Hormone Deficiency (GH
Slide 2: Disclosures
Disclosures Will Charlton, MD, Daniela Rogoff, MD, PhD, Eric Humphriss, MBA, and Kelly Di Trapani, RN, BSN, BA, are employees of Versartis, Inc Philippe F. Backeljauw, MD, is a consultant for Versartis, Inc Somavaratan (VRS-317) is an investigational agent
Slide 3: Growth Hormone and Glucose Homeostasis
Growth Hormone and Glucose Homeostasis Møller N and Jørgensen JOL. Endocrine Rev 2009;30(2):152-177; Clemmons DR. J Clin Investigation 2004;113:25-27. Control of carbohydrate (CHO) and lipid metabolism reflects interplay of nutrient availability, insulin, growth hormone (GH), IGF-I, interactions bet
Slide 4: Endogenous GH Exerts Different Effects during Fasting & Fed States
Endogenous GH Exerts Different Effects during Fasting & Fed States In the fed state, GH-induced stimulation of IGF-I and insulin is important for anabolic storage and growth of: Lean Body Mass (LBM) Adipose tissue Glycogen reserves During fasting/catabolic states, GH predominantly stimulates the rel
Slide 5: Effects of Growth Hormone Deficiency on Glucose Homeostasis
Effects of Growth Hormone Deficiency on Glucose Homeostasis In children and adults with GHD, loss of counterregulatory effects of GH results in dysregulated glucose homeostasis1 GHD Children GHD Adults Hyperresponsiveness to insulin1 Proneness to hypoglycemia1 Delayed recovery from hypoglycemia foll
Slide 6: General Effects of Exogenous Growth Hormone
General Effects of Exogenous Growth Hormone Change from an insulin sensitive state to a more insulin resistant state Elevated fasting glucose and insulin (INS > GLU) Elevated glucose and insulin responses to meals (INS > GLU) Increased IGF-I and IGFBPs Changes usually modest and within the normal ra
Slide 7: Consensus from 2016 Growth Hormone Safety Workshop: Metabolic Risk
Consensus from 2016 Growth Hormone Safety Workshop: Metabolic Risk Pediatric GHD Very low incidence of developing glucose intolerance or overt type 2 diabetes mellitus (DM) during rhGH treatment Lifetime risk of glucose intolerance and type 2 DM higher than background population in a number of condi
Slide 8: Effects of rhGH on Insulin Sensitivity in GHD
Effects of rhGH on Insulin Sensitivity in GHD Treatment of GHD with daily rhGH reduces insulin sensitivity, with effects correlating positively to dose and inversely with duration of treatment1 While rhGH-treated GHD adults predisposed to DM are prone to impaired glucose tolerance or overt DM, child
Slide 9: Methods
Methods 64 subjects received somavaratan for 6 months in the Phase 1b/2a study 60 elected to remain on somavaratan in the open-label, long-term safety study (13VR3, VISTA) All patients transitioned to 3.5 mg/kg twice-monthly by the 6-month time point in VISTA (after 12 months total somavaratan expos
Slide 10: Patient Demographics and Baseline Characteristics
Patient Demographics and Baseline Characteristics Subjects Enrolled in VISTA Study (n=60) Baseline age, years, mean (SD) 7.8 (2.4) Gender, n (%) Female 26 (43%) Male 34 (57%) Race, n (%) White 50 (83%) Asian 4 (7%) Black or African American 3 (5%) American Indian or Alaska native 1 (2%) Other 2 (3%)
Slide 11: HbA1c in Diagnosis of Diabetes Mellitus
HbA1c in Diagnosis of Diabetes Mellitus HbA1c % mmol/mol NICE Guidelines1 Normal Below 6.0% < 42 High Risk 6.0% to 6.4% 42 to 47 Diabetes ≥ 6.5% or over ≥ 48 American Diabetes Association 2016 Guidelines2 Normal Below 5.7% < 39 Prediabetes 5.7 to 6.4% 39-46 Diabetes ≥ 6.5% ≥ 48 1Type 2 diabetes: pre
Slide 12: Results: Individual Subjects with Elevated HbA1c in Study Period
Results: Individual Subjects with Elevated HbA1c in Study Period Modest HbA1c Changes in a Few Individual Subjects No Clear Pattern NICE WHO High Risk Diabetes ADA Prediabetes Subjects with elevated HbA1c in Study Period (n=8)
Slide 13: Results: Mean HbA1c Over Time in All Subjects
Results: Mean HbA1c Over Time in All Subjects HbA1c was Stable in Pre-Pubertal Children Treated with Somavaratan, and No Subjects Developed Overt DM NICE WHO High Risk Diabetes ADA Prediabetes No changes in mean HbA1c were observed with increased exposure to somavaratan No development of overt diabe
Slide 14: Conclusions
Conclusions HbA1c was stable in pre-pubertal GHD children treated with somavaratan Individual subjects (n=8) showed minor changes in HbA1c over time, and no subjects developed diabetes mellitus These findings suggest that somavaratan does not elicit detrimental effects on insulin sensitivity in pre-
Slide 15: Acknowledgments
Acknowledgments Investigators & Study Coordinators Patients and their Caregivers ResearchPoint Global